ReviewCureus2025
HIV Prevention Among People Who Inject Drugs (PWID): A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Barriers and Facilitators of Oral PrEP Uptake Against HIV Among Selected Priority Populations: A Global Perspective.Current HIV/AIDS reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People who inject drugs (PWID) face a significantly higher risk of HIV infection than the general population. Effective prevention for this group depends on combining several strategies: needle and syringe programs (NSPs), opioid agonist therapy (OAT), antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP), overdose prevention, and changes to structural and policy environments. This narrative review draws on evidence published between 2000 and 2024, including systematic reviews, clinical trials, surveillance reports, and global health guidelines. Programs that offer high coverage of NSPs and OAT have consistently been shown to reduce HIV incidence. ART helps lower viral load and prevents transmission, while both daily and long-acting PrEP offer additional protection for those at risk. However, access remains limited, particularly in low- and middle-income countries, due to criminalization, stigma, and a lack of investment in harm reduction services. Outcomes vary widely by region. In places like Portugal and Canada, where policies support decriminalization and integrate harm reduction into routine care, HIV incidence among PWID has dropped significantly. In contrast, countries that maintain punitive drug laws, such as Russia, continue to struggle with sustained epidemics. Reducing HIV transmission in this population will require expanding access to proven interventions, integrating services more effectively, and reforming policies that act as barriers to care. Priorities moving forward include scaling up NSP and OAT, addressing gender-based inequities, reducing stigma, and aligning national policies with international harm reduction standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.